Candido R, Gaiotti S, Giudici F, et al
One important distinction involves the manufacturing oversight and regulatory pathway associated with FDA-approved products versus compounded medications prepared through licensed pharmacy channels
While research findings are promising, human experiences with GLP-1 medications are not identical
Patients with untreated sleep disorders, patients pregnant or planning pregnancy, patients with active cancer, and patients with unaddressed hormone conditions are not candidates without coordination first
While some rat studies raised initial worries, none have shown that BPC-157 directly causes or speeds up cancer development
Powders now make up 61.3% of GLP-1-related nutritional procurement across institutional healthcare settings